Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Craig E Cole"'
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Many studies have documented racial, socioeconomic, geographic, and other disparities for United States (US) patients with multiple myeloma pertaining to diagnosis and frontline management. In contrast, very little is known about disparities
Externí odkaz:
https://doaj.org/article/831b0abdd6fd4c0ebc39d17a82b1623e
Autor:
Josh N. Vo, Yi-Mi Wu, Jeanmarie Mishler, Sarah Hall, Rahul Mannan, Lisha Wang, Yu Ning, Jin Zhou, Alexander C. Hopkins, James C. Estill, Wallace K. B. Chan, Jennifer Yesil, Xuhong Cao, Arvind Rao, Alexander Tsodikov, Moshe Talpaz, Craig E. Cole, Jing C. Ye, Multiple Myeloma Research Consortium, P. Leif Bergsagel, Daniel Auclair, Hearn Jay Cho, Dan R. Robinson, Arul M. Chinnaiyan
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
The genetic factors involved in disease progression and drug resistance in multiple myeloma (MM) are varied and complex. Here, genomic and transcriptomic profiling of 511 relapsed and refractory MM patients reveals genetic alterations in several onco
Externí odkaz:
https://doaj.org/article/f655f451b78e4e7097fa8cd313e2e43d
Publikováno v:
The American Journal of Medicine. 136:33-41
Multiple myeloma is the second most common hematologic malignancy in the United States and the most common hematologic malignancy among Blacks/African Americans. Delay in diagnosis is common and has been associated with inferior disease-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23082b92f891aca9604cfebac2fed1fa
https://doi.org/10.1016/j.amjmed.2022.08.030
https://doi.org/10.1016/j.amjmed.2022.08.030
Publikováno v:
Cureus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dea2de408af2549b6aba3b0ddbbccfb
https://doi.org/10.7759/cureus.37455
https://doi.org/10.7759/cureus.37455
Autor:
Benjamin A Derman, Jeffrey A. Zonder, Donna Reece, Craig E. Cole, Jesus G. Berdeja, Andrew T. Stefka, Ajay Major, Andrew Kin, Kent A Griffith, Jagoda Jasielec, Andrzej J Jakubowiak
Publikováno v:
Blood Advances.
We conducted a phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) followed by another cohort of KPd with daratumumab (Dara-KPd) in relapsed/refractory multiple myeloma. The primary endpoints were identification of a maximum tolerat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5df6b5b1ab3e6b1b5128fa42fb8fd022
https://doi.org/10.1182/bloodadvances.2022008866
https://doi.org/10.1182/bloodadvances.2022008866
Autor:
Meletios A. Dimopoulos, Cristina Gasparetto, Maeva Hellet, Pekka Anttila, Sandrine Macé, Marcelo Capra, Jian Y Yin, Matthew W Jenner, Eduardo Yanez Ruiz, Sara Bringhen, Vania Hungria, Vladimir I. Vorobyev, Rao Saleem, Craig E. Cole, Bruno Paiva, Michele Cavo, Ravi Vij
Publikováno v:
Blood
This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ≥3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b155c38aec5b28a10a6674ed65d2f0f
http://hdl.handle.net/10138/334769
http://hdl.handle.net/10138/334769
Autor:
Ravi Vij, Claire Brillac, Jesús F. San-Miguel, Marielle Chiron, Corina Oprea, Parameswaran Hari, Nikoletta Lendvai, Jeffrey A. Zonder, Cristina Gasparetto, Thomas Martin, Joshua R. Richter, Meletios A. Dimopoulos, Joseph R. Mikhael, Eric Charpentier, William I. Bensinger, Enrique M. Ocio, Shaji Kumar, Craig E. Cole, Jonathan L. Kaufman
Publikováno v:
Leukemia . 2020 Dec;34(12):3298-3309
Leukemia
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Leukemia
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
A Phase 2 dose-finding study evaluated isatuximab, an anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM; NCT01084252). Patients with ≥3 prior lines or refractory to both immunomodulatory drugs and proteasome inhibitors (d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e9b9e34babe8d3899acf31fcaaf4f0
http://hdl.handle.net/10902/21543
http://hdl.handle.net/10902/21543
Autor:
Sundar Jagannath, Luciano J. Costa, Cassandra Choe-Juliak, A. Keith Stewart, Divaya Bhutani, Ravi Vij, Jeffrey A. Zonder, Jean Richard Saint-Martin, Dan T. Vogl, Craig E. Cole, David Dingli, Rafat Abonour, Michael Kauffman, Rafael Fonseca, Ajay K. Nooka, Sharon Shacham, Terri L. Parker, Robert F. Cornell, Rachid Baz, James E. Hoffman, David Kaminetzky, David S. Siegel, Andrew Yee, Gregory J. Ahmann, Carla Picklesimer, Ilsel Lopez, Joshua R. Richter, Ajai Chari, Carol Ann Huff, Andrzej Jakubowiak, Gary J. Schiller, Scott Van Wier
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 9
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncopr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a8485966f48847a486acafd4f0bd10
https://doi.org/10.1200/jco.2017.75.5207
https://doi.org/10.1200/jco.2017.75.5207
Autor:
Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman
Publikováno v:
Blood. 138:2758-2758
Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c39297ff6c758f9ec1f17f02de5214b
https://doi.org/10.1182/blood-2021-153922
https://doi.org/10.1182/blood-2021-153922
Autor:
Yi-Mi Wu, P. Leif Bergsagel, Dan R. Robinson, Moshe Talpaz, J Christine Ye, Brian Parkin, Erica L. Campagnaro, Malathi Kandarpa, Liying Chen, Daniel Auclair, Veerabhadran Baladandayuthapani, Craig E. Cole, Christopher Su, Josh N. Vo, Arul M. Chinnaiyan, Avery Polk, Jennifer Yesil, Jason Chen
Publikováno v:
Blood. 136:45-46
BACKGROUND Aneuploidy, defined by abnormal copy number changes of chromosomes, contributes to genome instability in multiple myeloma and has potential prognostic impact. Previous research has explored transcriptional pathways affected by aneuploidy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4fae25a128e05dffb76e6e77ed160dd
https://doi.org/10.1182/blood-2020-134558
https://doi.org/10.1182/blood-2020-134558